Common Treatment May Be Removed In Alcoholic Hepatitis Trials
Executive Summary
Given effect corticosteroids have on patients, US FDA asks whether they can be excluded from use in alcoholic hepatitis clinical trials.
You may also be interested in...
Pipeline Watch: Phase III Starts With NSR-REP1 Gene Therapy, ALLN-177 And BIVV009
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Progress With Avelumab, Ixekizumab And Eravacycline
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Target's NASH Study Captures Real World Data, Helps Partners With Trial Design
Longitudinal observational study of NASH patients provides data to companies to help them better understand disease; Target PharmaSolutions conducting similar efforts in primary biliary cholangitis, hepatocellular carcinoma, and inflammatory bowel disease.